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Abstract
Topical DNA vaccination (DermaVir) facilitates antigen presentation to naive T cells. DermaVir immunization in mice, using HIV-1 Env and
Gag, elicited cellular immune responses. Boosting with HIV-1 gp120 Env and p41 Gag augmented Th1 cytokine levels. Intramuscular DNA
administration was less efficient in priming antigen-specific cytokine production and memory T cells. In rhesus macaques, DermaVir
immunization induced Gag- and Env-specific Th1 and Th2 cytokines and generation of memory T cells. Boosting of DermaVir-primed serum
antibody levels was noted following gp140(SHIV89.6P)/p27(SIV) immunization. Rectal challenge with pathogenic R5-tropic SHIV162P3
resulted in control of plasma viremia (4/5 animals) that was reflected in jejunum, colon and mesenteric lymph nodes. An inverse correlation was
found between Gag- and Env-specific central memory T cell responses on the day of challenge and plasma viremia at set point. Overall, the topical
DermaVir/protein vaccination yields central memory T cell responses and facilitates control of pathogenic SHIV infection.
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Based on immunological studies conducted in several
cohorts of HIV-1-infected individuals, it has been hypothesized
that broad cellular immunity and high titered neutralizing
antibodies are inversely correlated with HIV-1 disease progres-
sion in humans (Pantaleo and Fauci, 1996; Soudeyns and
Pantaleo, 1999). Both CD8+ cytotoxic T lymphocytes (CTLs)
(Benito et al., 2004; Kong et al., 2003; Otero et al., 2004) and
CD4+ helper T cells have been shown to play a critical role in
the induction of cellular immune responses and maintenance of⁎ Corresponding authors. Fax: +1 301 468 9466.
E-mail addresses: anthony.cristillo@ablinc.com (A.D. Cristillo),
ranajit.pal@ablinc.com (R. Pal).
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doi:10.1016/j.virol.2007.04.012memory T cells (Bevan, 2004; Estcourt et al., 2004; Lichterfeld
et al., 2004; Sun et al., 2004). Recently, the importance of
central memory T cell responses in the control of viremia and
survival of macaques following viral challenge and infection
has been demonstrated by several laboratories (Letvin et al.,
2006; Mattapallil et al., 2006; Vaccari et al., 2005).
In general, it has been demonstrated that plasmid DNA
priming by systemic administration elicits modest but detectable
cellular and humoral immune responses that requires a boost to
augment these immune responses (Amara et al., 2001; Barnett et
al., 1997; Barouch and Letvin, 2000; Cristillo et al., 2006; Earl et
al., 2001; Franchini et al., 2004; Gomez-Roman and Robert-
Guroff, 2003; Pal et al., 2005, 2006a; Reyes-Sandoval et al.,
2004; Rose et al., 2001; Santra et al., 2004; Sumida et al., 2004;
Zhao et al., 2003). In order to increase the level of priming by
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investigated. Approaches include the use of adjuvants and
immunomodulators that target antigen presenting dendritic cells
such as toll-like receptor agonists (Dumais et al., 2002; Horner et
al., 2001; Kojima et al., 2002; Moss et al., 2000; Tritel et al.,
2003; Wille-Reece et al., 2005). Other strategies include the use
of immunomodulatory agents such as cytokines to influence
Th1/Th2 polarization, and enhance generation ofmemory Tcells
(Ahlers et al., 2001; Bolesta et al., 2006; Boyer et al., 2005; Jiang
et al., 2006; Kutzler et al., 2005).
An alternative novel immunization strategy is the topical
DermaVir immunization. Vaccine antigens are encoded in a
plasmid DNA formulated into a mannosylated nanoparticle to
target specialized dendritic cells under the surface of the skin
termed Langerhans cells (LCs) (Lisziewicz et al., 2006). Topical
immunization with DermaVir has been shown to result in the
efficient expression of the plasmid DNA-encoded antigens in
dendritic cells which, in turn, can present antigens to naive T
cells in secondary lymphoid organs, such as lymph nodes,
leading to the generation of antigen-specific memory T cell
responses (Lisziewicz et al., 2005a). In therapeutic studies,
DermaVir immunization has been shown to be efficacious in
suppressing the viral load rebound following treatment inter-
uption (Lisziewicz et al., 2005b; Lori et al., 2005).
Subunit structural viral proteins, formulated in QS-21
adjuvant, have been shown to boost DNA-primed cellular and
humoral immune responses in mice and nonhuman primates
(Cristillo et al., 2006; Pal et al., 2005, 2006a). We here report
immunogenicity of a novel prophylactic vaccine regimen that
combined a topical DermaVir priming with an intramuscular
protein boost in both murine and nonhuman primate models.
Efficacy of this vaccine regimen was also evaluated in macaques
following mucosal challenge with a pathogenic SHIV isolate.
Our results show that this topically administered DermaVir
formulation followed by protein boost elicits both CD4- and
CD8-specific central memory responses capable of controlling
plasma viremia following primary phase of infection.
Results
Induction of Th1 and Th2 cytokines in CD8 and CD4 T cells
following DermaVir prime and protein boost immunizations in
mice
To evaluate the immunogenicity of topically administered
HIV-1 antigens in mice, CMV-driven plasmid DNA wasFig. 1. Env- and Gag-specific Th1 and Th2 cytokine production in T cells elicit
Immunizations, splenocyte collections, intracellular cytokine staining and ELISPOT
Env or Gag peptide (1 μg/ml) stimulation, intracellular TNFα and IL-4 production in
measured in splenocytes of mice (n=7 per group) immunized with one DermaVir adm
or with the combined three DermaVir plus one protein administration (D3P1). Mea
production in each group and are graphically represented for Env (A)- and Gag (B)-sp
splenocytes of animals immunized with DermaVir and protein as indicated (C). Foll
CD4−CD44+CD62L+ (D) and CD4+CD44+CD62L+ (E) memory T cells was measure
administration (D1), three DermaVir administrations (D3), protein/QS-21 alone (P1)
Cytokine levels from splenocytes are also graphically represented for mice that were i
single intramuscular protein boost (DNA3(IM)P1).formulated with PEIm and dextrose. CMV, but not LTR-driven
promoter constructs were used since CMV-driven plasmids are
known to express very efficiently in mice. BALB/c mice were
topically immunized (one or three times) with DermaVir
according to the outlined schedule (Materials and methods).
Alternatively, mice received three DermaVir administrations
followed by a single intramuscular protein (gp120 and p41) in
QS-21 formulation boost or received protein/QS-21 alone. In
order to assess the contribution of CD8 and CD4 T cells in the
cellular immune responses elicited by the vaccine, induction of
Th1 and Th2 cytokines in splenocytes was evaluated. From
these analyses, it was evident that a single DermaVir im-
munization induced Env (Fig. 1A)- and Gag (Fig. 1B)-specific
production of intracellular TNFα and IL-4, surrogate markers of
Th1 and Th2 cytokines respectively, in both CD8 and CD4 T
cells. Levels of TNFα increased with repeated DermaVir
immunizations as well as by protein boost.
To assess levels of effector T cell responses following
immunizations, IFNγ ELISPOT assays were performed. While
the number of IFNγ spots were below the threshold of detection
following DermaVir immunization, Env (Fig. 1C) and Gag
(data not shown) antigen-specific IFNγ production was greatly
enhanced following a single protein boost.
To further assess the production of Th1 cytokines in T cells
following DermaVir immunization as compared to DNA
delivered by IM route, pooled splenocytes and lymph nodes of
immunized mice were stimulated ex vivo with Gag and Env
peptide pools as described (Materials and methods). Intracellular
cytokine staining was performed and TNFα cytokine levels were
measured in CD4-positive and -negative T cells of memory cell
phenotype (CD44+CD62L+). As shown in Fig. 1, very low levels
of Gag- and Env-specific TNFα production were noted in both
CD4-CD44+CD62L+ (Fig. 1D) and CD4+CD44+CD62L+ (Fig.
1E) T cell subpopulations following DermaVir immunization and
this response was significantly augmented by protein boost. By
contrast, Th1 cytokine levels were not elevated to the same extent
when immunization was performed by either intramuscular
protein/QS-21 administration or by intramuscular naked DNA
priming followed by a protein/QS-21 boost (Fig. 1D, E). Similar
results were also noted in lymph nodes (data not shown).
CTL activity elicited by a single DermaVir immunization is
enhanced following repeated administrations in mice
Given that cytokine production was modulated by this
vaccine regimen, it was of interest to next assess whether theseed by topical DermaVir prime/protein boost immunization in BALB/c mice.
assays were carried out as described (Materials and methods). Following a 5-h
CD3+CD8+ (A, B, upper panel) and CD3+CD4+ (A, B, lower panel) T cells was
inistration (D1), three DermaVir administrations (D3), protein/QS-21 alone (P1),
n values were calculated for the percentage of peptide-specific TNFα or IL-4
ecific responses. IFNγ production (spots per million PBMC) was measured from
owing peptide stimulation, intracellular TNFα production was also measured in
d in pooled splenocytes of mice (n=7 per group) immunized with one DermaVir
, or with the combined three DermaVir plus one protein administration (D3P1).
mmunized with three intramuscular administrations of naked DNA followed by a
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DermaVir immunization was found to elicit both Env- and Gag-
specific CTL activity as measured by a single cell-based
fluorogenic cytotoxicity assay that detects caspase activation
(Fig. 2). This assay provides a very sensitive measure of
memory T cell function as splenocytes and pooled lymph node
lymphocytes are expanded for 7 days by peptide stimulation.
One single DermaVir immunization elicited Gag-specific
memory CTL activity in splenocytes (Fig. 2B, upper right
panel), whereas Env-specific CTL activity was not detected
above levels found in control samples (Fig. 2B, upper left
panel). Three DermaVir vaccinations, however, increased both
Gag- and Env-specific CTL activity. As expected, memory CTL
activity was not detected in mice immunized with protein/
QS-21 alone. Boosting of DermaVir-primed mice with QS-21-
formulated protein did not further augment the CTL activity.
Levels of CTL activity were found to be markedly higher
following DermaVir immunization than those noted following
priming of mice with DNA or by a DNA prime/protein boost
immunization where the DNA was administered by IM route
(Fig. 2C).
Given that topical DermaVir vaccination targets Langerhans
cells and facilitates presentation of antigens to naive T cells in
secondary lymphoid organs, we evaluated memory CTL
responses in pooled lymph nodes of immunized mice. As
noted in Fig. 2B, Gag (lower right panel)- and Env (lower left
panel)-specific CTL activity was indeed detected in lymph
nodes following one DermaVir immunization. While more
DermaVir immunizations could not further augment the potent
Gag-specific CTL activity, they were able to increase the less
potent Env-specific CTL activity noted. Following a single
protein boost, Gag-specific CTL activity did not increase above
levels following three DermaVir immunizations. While Env-
specific CTL activity was enhanced following a single protein
boost in this study, this response was not reproducible in
subsequent studies. As expected, CTL activity was not detected
in pooled lymph nodes of mice immunized with protein/QS-21
alone.
Induction of Th1 and Th2 cytokines in rhesus macaques
following topical DermaVir prime and intramuscular protein
boost immunizations
Rhesus macaques were immunized with DermaVirSHIV
according to the outlined schedule (Materials and methods).
Consistent with the observations made in mice (Fig. 1), two
DermaVir vaccinations elicited secretion of Th1 and Th2 cyto-
kines as quantitated by cytometric bead array, from macaqueFig. 2. CTL activity elicited by DermaVir immunization. Immunizations, splenocy
(Materials and methods). CTL density blots for representative splenocytes from BALB
immunizations following Env (A, left panel) or Gag (A, right panel) peptide pool stim
CTL values (=test sample CTL activity−no peptide control CTL activity−naive sam
group (n=7 mice per group) are graphically represented for splenocytes (B upper pan
that received one DermaVir (D1), three DermaVir (D3), protein/QS-21 alone (P1) or t
(B). These data were found to be reproducible in a second murine study. Corrected C
with IM administered DNA plus a protein/QS-21 boost immunization (DNA(IM)+ pPBMCs stimulated with Env or Gag peptide pools (Fig. 3).
DermaVir immunization elicited variable levels of Gag- and/or
Env-specific Th1 (TNFα, IFNγ, IL-2; Fig. 3A) and Th2 (IL-6,
IL-5, IL-4; Fig. 3B) cytokines in the five immunized primates.
In macaque M34, however, an absence of Gag- and Env-
specific IL-2 and IFNγ production was noted and a modest but
detectable level of TNFα. Similarly, the absence of Gag- and
Env-specific IFNγ was demonstrated in macaque M37.
Following protein immunization of DermaVir-primed maca-
ques, Th2 cytokine levels were found to be further enhanced
while the levels of Th1 cytokines were minimally affected
suggesting that the response persists following the boosting
phase of immunization (data not shown).
Central memory T cell responses elicited following DermaVir/
protein immunizations
To further evaluate the longevity of the CMI response
following DermaVir/protein immunizations, we used an in-
tracellular cytokine staining procedure and evaluated whether
this prime-boost regimen could generate antigen-specific
central memory T cells capable of producing Th1 cytokines
on the day of viral challenge. Gag-specific TNFα, IL-2 and
IFNγ production was detected in CD8 central memory
(CD45RA−CCR7+) T cells from four (M33, M38, M35, M37)
of the five immunized macaques (Fig. 4A). While Env-specific
TNFα, IL-2 and IFNγ production was noted in the CD8 central
memory T cells of macaques M33 and M38, that of M35 and
M37 was limited to TNFα and IFNγ with minimal or no IL-2.
In contrast, M34 showed minimal Gag-specific CD8 central
memory responses and no Env-specific responses. When CD4
central memory T cells were evaluated, all immunized mac-
aques demonstrated Gag-specific TNFα and IFNγ production
with minimal or no Env-specific responses (Fig. 4B). Effector
memory (CD45RA−CCR7−) T cell responses were also noted in
macaques on the day of challenge and were found to be
predominantly Gag-specific CD4+ responses and to a lesser
extent CD8+ responses (data not shown). By contrast, Env-
specific effector memory responses were not detected in any of
the macaques tested (data not shown). Samples were not
evaluated for central/effector memory phenotypes or their
associated Th1 responses after each individual immunization in
order to avoid reporting “short-lived” memory responses and
thereby, overestimating the level of memory T cells. We did,
however, assess memory responses 2 weeks following the final
protein immunization and found central memory T cell levels to
be similar, albeit elevated, compared to levels observed for
samples collected on the day of challenge (data not shown).te and lymph node collections and CTL assays were carried out as described
/c mice immunized with one (A upper panel) or three (A, lower panel) DermaVir
ulation are shown with percentages of caspase-positive cells indicated. Corrected
ple CTL activity) were determined and the mean values±standard error for each
el) and lymphocytes isolated from pooled lymph nodes (B lower panel) of mice
he combination of three DermaVir plus one protein/QS-21 (D3P1) immunization
TL values are also graphically represented for splenocytes of mice immunized
rotein) or with DNA alone (DNA (IM)) (C).
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Fig. 3. Env- and Gag-specific Th1 and Th2 cytokine production elicited by topical DermaVir immunization in rhesus macaques. At week 8, 2 weeks following the second topical administration of DermaVirSHIV, PBMCs
from immunized macaques were stimulated ex vivo with Env (SHIV89.6P) or Gag (SIVmac239) peptide pools (1 μg/ml) for 18 h as outlined (Materials and methods). Cell supernatants were assayed, by CBA, for Env- and
Gag-specific Th1 (TNFα, IL-2, IFNγ; A) and Th2 (IL-6, IL-4, IL-5; B) cytokines according to the manufacturer's protocol as described (Materials and methods). Acquisition of samples was carried out using a
FACScalibur cytometer (BD Biosciences) and quantitation of cytokines was performed using the BD CBA 6-Bead Analysis Software. Summary graphs are shown for macaques M33, M34, M38 M35 and M37.
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Fig. 4. DermaVir prime/protein boost immunization of rhesus macaques elicits
Env- and Gag-specific Th1 cytokine production in CD8+ and CD4+ central
memory T cells. Immunizations were performed as outlined (Materials and
methods) and assessment of central memory T cells expressing Th1 cytokines
was performed as described (Materials and methods). For macaques M033,
M034 and M038, assays were performed on PBMCs following three DermaVir
primes and two protein/QS-21 boosts (D3P1). For macaques M035 and M037,
assays were conducted on PBMCs following two DermaVir primes and one
protein/QS-21 boost (D2P1). Stacked bar graphs are shown for the percentage of
CD8+ (A) and CD4+ (B) central memory T cells that produce TNFα (white fill
bars), IFNγ (black fill bars) and IL-2 (grey fill bars) cytokines in response to Env
and Gag stimulation as indicated.
Fig. 5. Binding antibody titers induced by DermaVir prime/protein boost
immunization. Immunizations were performed as outlined (Materials and
methods). All macaques (M033, M034, M038, M035 and M037) were
immunized with two topical administrations (weeks 0, 6) of DermaVirSHIV.
Macaques M35 and M37 were boosted once intramuscularly (week 12) with
SHIV89.6P gp140 and SIV p27 Gag proteins formulated in QS-21 adjuvant.
Macaques M33, M34 and M38 received similar protein administrations on
weeks 18 and 37. Macaque serum samples of animals were tested for antibodies
against SHIV89.6P gp140 protein. Serum titers were determined as the highest
dilution of immune serum-producing ELISA values (A450 nm) greater than or
equal to two times the binding detected with a corresponding dilution of pre-
immune serum.
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enhanced following protein boost
Since cellular immune responses were detected following
two DermaVir immunizations, it was of interest to determine
whether antibodies were also induced following immunization
by DermaVir alone. Following two DermaVir immunizations,
antibodies to Env (Fig. 5) were not detected by ELISA. Three
macaques (M33, M34, M38) were given one additional
DermaVir administration in order to assess whether a third
immunization could facilitate detection of anti-gp140 (or anti-
p27) antibodies. Again, antibodies to SHIV89.6P gp140 (Fig.
5) were below the limit of ELISA detection. After these
macaques were boosted with protein, substantial antibodytiters to Env (Fig. 5) were noted. Antibody titers were
comparable in macaques primed with two or three DermaVir
immunizations. As observed in other DNA prime/protein
boost vaccines (Pal et al., 2006a), these anti-Env antibody
titers declined with time following an 18-week rest period
(Fig. 5). However, such responses were enhanced significantly
when macaques received an additional immunization with
89.6P gp140.
Four out of five DermaVir prime/protein boosted macaques
controlled viremia following rectal challenge with pathogenic
SHIV
Since the majority of the heterosexual transmissions of HIV-
1 takes place via mucosal route and this regimen is based upon
topical administration, we wanted to test the efficacy of this
vaccine against a heterologous viral challenge administered via
mucosal route. An R5 SHIV, SHIV162P3, was selected for this
challenge as this virus has been shown to transmit efficiently by
mucosal route (Harouse et al., 2001). When sera from the
day of challenge were tested for neutralizing antibodies to
SHIV162P3, none were detected (data not shown). Following
rectal challenge of macaques with pathogenic R5 SHIV162P3,
four (M33, M38, M35, M37) out of five animals were found to
control viremia at set point when compared to non-immunized/
infected macaques (Fig. 6). One particular macaque, M38,
showed a delayed peak viremia and reduction in set point
viremia. A Spearman rank correlation analysis supported an
inverse correlation between the percentage of Env-specific
Fig. 6. Plasma viral RNA load in DermaVir/protein-immunized macaques challenged with SHIV162P3 by rectal route. Plasma virus load was measured, using
NASBA technology, for DermaVir prime and protein/QS-21 boosted animals following rectal challenge with SHIV162P3 as described (Materials and methods). Values
for M33 (A), M34 (B), M38 (C), M35 (D) and M37 (E) immunized/infected macaques (A–E, solid lines) are graphically compared to mean values obtained for
infected naive/control animals (A–E, dotted line). Statistical significance (p=0.041) was demonstrated between immunized/infected animals and naive/infected
animals using area under the RNA load curve (days 42–84) followed by the Mann–Whitney non-parametric test.
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level of plasma viremia at set point (r=−0.900, p=0.042). A
similar correlation was found for the percentage of Gag-specific
CD8+CD45RA−CCR7+IL2+ cells on the day of challenge and
the level of plasma viremia at set point (r=−0.900, p=0.042).
We next evaluated mucosal tissues (jejunum, colon), at sacrifice,
for the presence of viral RNA and proviral DNA in immunized/
challenged animals (Fig. 7). Tissues from naive (non-immu-
nized) macaques were not available for this evaluation and hence
are not included. Our results demonstrated that the control of
plasma viremia, observed in the majority of immunized/
challenged macaques, was also reflected in tissue viral RNA
and proviral DNA load. In contrast, the animal that failed to
control plasma viremia, M34, presumably due to lack of centralmemory Tcells, exhibited high levels of RNA and proviral DNA
load in tissues.
Discussion
While neutralizing antibodies are critical components of anti-
HIV immunity, there is also increasing evidence that empha-
sizes the importance of cytotoxic T lymphocytes as necessary
effectors in controlling HIV-1 (Gruters et al., 2002; Klenerman
et al., 1996; Kong et al., 2003; Otero et al., 2004; Rasmussen et
al., 2002; Wagner et al., 1999; Woodberry et al., 2003; Yu et al.,
2002). To date, one major obstacle that has been encountered in
HIV-1 vaccine development has been the generation of a
vaccine that elicits both humoral and cellular immune responses
Fig. 7. Tissue viral RNA load and tissue proviral DNA in DermaVir/protein-immunized macaques following rectal challenge with SHIV162P3. Jejunum, colon and
mesenteric lymph nodes were harvested from immunized/challenged animals on the day of sacrifice. Tissue viral RNA load was quantitated using NASBA technology
(A) and proviral DNA load was quantitated by TaqMan real-time PCR (B) as described (Materials and methods). The normalized value of the SHIV proviral load was
calculated as SHIV copy number/albumin copy number×2×106 and expressed as the number of SHIV copies per 106 cells.
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vaccine strategies currently being tested in preclinical and
clinical trial settings are aimed at augmenting such immune
responses. Prime-boost and multiple antigen-based vaccine
strategies hold promise in bolstering both arms of the immune
system. These include but are not limited to the following: DNA
prime/live vector boost (e.g., MVA, ALVAC, adenovirus,
fowlpox) (Allen et al., 2000; Amara et al., 2001; Buge et al.,
2003; Hanke et al., 2002; Sharpe et al., 2003; Wee et al., 2002);
live vector prime/protein boost (Earl et al., 2002; Gomez et al.,
2001; Pal et al., 2002); live vector prime/live vector boost (e.g.,
MVA, adenovirus) (Gherardi et al., 2003; Shiver et al., 2002);
DNA prime/protein boost (Barnett et al., 1997; Billaut-Mulot et
al., 2000; Cristillo et al., 2006; Letvin et al., 1997; Lu, 2003;O'Neill et al., 2002; Pal et al., 2004, 2005, 2006a, 2006c;
Rasmussen et al., 2002).
Novel antigen delivery methods, preferably non-invasive
(needle-free) and directed toward antigen presenting cells (APC)
on the mucosal surface, could also offer advantages compared to
other vaccine strategies where immunogens are primarily
administered systemically. To this end, DermaVir, a topical
vaccination strategy, represents a novel approach to deliver and
express DNA-encoded antigens in dendritic cells. The vaccine is
formulated to form a mannosylated nanoparticle consisting of
three components to facilitate targeting of epidermal Langerhans
cells: plasmid DNA-encoded antigens, polyethylenimine-
mannose (PEIm) and dextrose (Lisziewicz et al., 2003;
Lisziewicz et al., 2001). Topical DermaVir vaccination has
206 A.D. Cristillo et al. / Virology 366 (2007) 197–211been shown to facilitate presentation of DNA-encoded HIV
antigens by dendritic cells in lymphoid organs to T cells and
subsequent generation of HIV-specific memory T cells.
Supporting the proposed mechanism of action, we found
mice receiving a single topical DermaVir vaccination elicited
HIV-specific CTL activity in the draining lymph nodes (Fig. 2).
Splenocytes of mice immunized with a single DermaVir
immunization also demonstrated Gag-specific memory CTL
activity, but levels were less than those measured in corres-
ponding lymph nodes. Env-specific CTL activity was not
detected in splenocytes following a single DermaVir immuni-
zation. These observations may reflect differences due to de-
livery of antigens into the muscle (IM) versus delivery to
antigen presenting Langerhans cells (DermaVir). Our findings
not only highlight the ability of DermaVir to prime cellular
immune responses, but are also consistent with the mechanism
of action where topically administered DermaVir results in
dendritic cell-mediated antigen presentation and T cell acti-
vation in draining lymph nodes (i.e., inguinal and axillary)
and the antigen-specific T cells subsequently migrating into
the spleen. Our findings are consistent with other reports
demonstrating that topical DNA immunization of HIV-1
antigens by other delivery methods induces robust cellular
(Belyakov et al., 2004; Liu et al., 2001; Partidos et al., 2004)
and humoral (Liu et al., 2001; Partidos et al., 2004) immune
responses in mice. When utilized for vaccination against other
pathogens (i.e., influenza virus), transcutaneous immunization
has also been shown to elicit systemic and mucosal cellular
and humoral immune responses (Ozaki et al., 2005; Skountzou
et al., 2006).
DermaVir contains a non-viral vector for DNA delivery and
therefore does not induce vector-specific immune responses.
Therefore, unlike viral vector vaccination approaches where
repeated immunizations may not be feasible, repeated DermaVir
vaccinations can be used to augment host immune responses. In
this manner, repeated DermaVir immunizations augmented
CTL activity compared to a single immunization (Fig. 2) and
were characterized by Th1 and Th2 cytokine production in both
mice (Fig. 1) and macaques (Fig. 3). Responses were further
shown to include contributions from both CD8+ and CD4+ T
cells in murine splenocytes (Fig. 1) and macaque PBMCs (Fig.
4). Surprisingly, CTL activity elicited by three DermaVir
immunizations in mice could not be further boosted by
intramuscular injection of QS-21-formulated protein (Fig. 2)
although there was a detected increase in effector T cell
responses as demonstrated by ELISPOT assay (Fig. 1C). Given
that naked DNA vaccination methods using IM or ID injection
elicit weak effector T cell responses that can be further increased
with protein immunization (Cristillo et al., 2006; Pal et al.,
2006a), it remains possible that delivery of plasmid DNA by
topical DermaVir sufficiently and optimally primes the cellular
response that cannot be further boosted with recombinant
proteins.
Previous studies have clearly demonstrated that humoral
responses can be primed using naked plasmid DNA, delivered
by ID, IM or gene gun administration, and can be further
augmented with recombinant protein boost (Cristillo et al.,2006; Pal et al., 2006a; Wang et al., 2005). We therefore
anticipated that topical DermaVir immunization would prime
antibody responses that could be further augmented following
intramuscular protein administration. While antibodies to
SHIV89.6P gp140 or SIV p27 could not be detected following
repeated DermaVir immunizations, a rapid increase in antibody
titers was noted following a single protein boost, thus,
suggesting that priming had taken place (Fig. 5). While binding
antibody titers were further increased following a second
protein boost in macaques, no neutralizing antibodies to
SHIV162P3 could be detected following immunization (data
not shown). Rectal challenge of macaques with SHIV162P3
demonstrated that priming with topical DermaVir and boosting
with protein/QS-21 by IM route resulted in a control of viremia
at set point for four of the five immunized macaques. Further
analyses revealed that on the day of challenge four of the five
immunized macaques exhibited Gag- and Env-specific central
memory CD8 and CD4 T cells capable of expressing Th1
cytokines. Consistent with other reports highlighting the
importance of central memory T cells in the control of viremia
(Letvin et al., 2006; Vaccari et al., 2005), an inverse correlation
was noted between the levels of CD8 and CD4 central memory
T cells on the day of challenge and plasma viral RNA loads at
set point. Further evaluation of mucosal tissues (jejunum,
colon), at sacrifice, for viral RNA and proviral DNA (Fig. 7)
demonstrated a consistent pattern of viremia as that noted in
plasma with one non-controlling macaque, M34, exhibiting
relatively higher tissue RNA and proviral DNA loads, as
compared to macaques that controlled viremia. Preliminary data
from our laboratories suggest that mucosal immune responses
may be induced following immunization with the topical
DermaVir prime/protein boost formulation (data not shown).
Thus, evaluating mucosal immune responses will be a focus of
future vaccine evaluations.
Overall, our studies demonstrate that DermaVir prime/
protein boost prophylactic HIV-1 vaccine regimen can elicit
robust cellular immune responses and generate central memory
T cells that are effective in controlling a pathogenic R5
SHIV162P3.
Materials and methods
Antigens
For DermaVir applications in mice, codon optimized HIV-1
env genes encoding subtype B (Ba-L), and p55 gag encoding
subtype C (96ZM651) were prepared as described (Cristillo et
al., 2006). For intramuscular administrations, multivalent DNA
from clades A, B, C and E and HIV-1 Gag proteins was prepared
as described (Cristillo et al., 2006). Both env and gag DNA
plasmids were prepared commercially (Althea Technologies,
CA) and were shown to contain N90% supercoil structure with
low endotoxin levels (b20 EU). For macaque immunizations,
DermaVirSHIV was constructed and formulated as described
(Lisziewicz et al., 2005a).
Recombinant gp120 (clade B) and SHIV89.6P gp140 proteins
were expressed in stably transfected CHO or 293 cells,
207A.D. Cristillo et al. / Virology 366 (2007) 197–211respectively, under control of the CMV promoter as described
(Cristillo et al., 2006). Both gp120 and gp140 genes were
cloned in frame with tPA signal peptide to achieve secretion of
the protein into the medium. Secreted gp120 or gp140 proteins
from the conditioned medium was purified by chromatography
using Galanthus nivalis lectin. Proteins were formulated with
QS-21 adjuvant (Antigenics Inc., Woburn, MA).
Recombinant HIV-1 HXB2 p41 protein was expressed and
purified from transformed BL21 (DE3) Escherichia coli. This
truncated Gag protein (p17 and p24 subunits of p55 precursor)
lacked the myristoylation site at the amino terminus of the
p17 subunit and encompassed the majority of CTL epitopes
identified in HIV-1 Gag. The p41 gene was constructed using
PCR to amplify the linked p17 and p24 gene subunits from
the gag gene of the HIV-1 clade B molecular clone HXB2.
The PCR products were cloned into the NdeI and NotI
restriction sites of pET23a (Novagen Inc., Madison, WI). The
pET23a utilizes the isopropyl b-D-thiogalactopyranoside
(IPTG)-inducible T7 promoter to promote high level expres-
sion of inserted genes, and contains an ampicillin resistance
marker for the selection of transformants. To facilitate the
purification of p41 from BL21 (DE3)-transformed competent
cells using nickel chromatography, the termination signal
followed a carboxy-terminal six-histidine tag. Following
nickel chromatography, reverse phase HPLC was performed
using a C-18 column to further purify the p41 Gag protein.
Native SIV p27 Gag was purified from the supernatant of
HUT78-infected cells.
Peptides
For the murine study, HIV-1 Env (BaL) and Gag (HXB2)
peptides were synthesized (Infinity Biotech Research and
Resource Inc., Aston, PA). For Clade B Env (Ba-L), 79
peptides (15-mers) with 11-amino-acid overlapping residues
were synthesized that comprise the gp120 Env protein
sequence and were resuspended in one peptide pool. For
Gag, 122 peptides (15-mers) with 11-amino-acid overlapping
residues were synthesized and resuspended in one peptide
pool. For the nonhuman primate study, SHIV89.6P Env and
SIMmac239 Gag peptides were obtained from the NIH AIDS
Research and Reference Reagent Program. Env and Gag
peptides were resuspended in single peptide pools and cells
were stimulated as indicated using a final peptide concentration
of 1 μg/ml.
Murine immunizations
BALB/c mice (5- to 7-week-old females) were immunized
with topically administered plasmid DNA formulated with
polyethylenimine-mannose (PEIm) and dextrose followed by
intramuscular protein administration (total volume=100 μl;
50 μl/site at 2 different sites) of pooled gp120 (BaL) and
p42 Gag in QS-21 adjuvant. The DNA immunogens were
comprised of codon optimized HIV-1 env (BaL) and gag
(Czm) genes under the control of a CMV promoter. This
topical formulation (200 μl) was applied on the back of eachmouse from the nape of the neck to the base of the tail.
Mice were divided into test and naive immunization groups.
Mice were immunized by one (D1) or three (D3) topical
DNA administrations. Selected mice were further immunized
with a single protein/QS-21 boost (D3P1). Alternatively,
one group of mice were immunized with protein alone by
IM route (P1) while another group received three DNA
immunizations by IM injection followed by a single protein
boost (DNA3(IM)P1). Immunizations were performed at
weeks 0, 2 and 4 and subsequent protein/QS-21 immuniza-
tion was conducted at week 6. Mice receiving DNA were
injected with a total of 100 μg of pooled DNA (16.6 μg of
each plasmid) and protein-boosted mice were additionally
vaccinated with a total of 30 μg of pooled (15 μg each)
protein (with 20 μg QS-21). Two weeks following the final
immunization, mice were sacrificed, splenocytes and lymph
nodes collected and immunogenicity assays were performed.
Test and naive control groups were comprised of a minimum
of five mice per group. Typically, the immunological
responses were minimal and often undetectable in naive,
control animals. However, to ensure that all values reported
for immunological assays represent vaccination-specific
immune responses, values obtained from unvaccinated,
naive control animals were subtracted from those of vacci-
nated animals. Additional murine studies were performed in
which mice were immunized with three intramuscular admi-
nistrations of DNA alone (100 μg; 16.6 μg of each plasmid
including HIV-1 env subtype A (92UG037.8), B (92US715.6,
Ba-L), C (96ZM651), E (93TH976.17) and HIV-1 gag subtype
C (96ZM651)) by IM route or with three DNA primes and one
protein/QS-21 (30 μg of pooled protein with 20 μg QS-21)
boost.
Macaque immunization and challenge
All animal studies were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) at
Advanced BioScience Laboratories. Five (M33, M34, M35,
M37 and M38) rhesus macaques (Macaca mulatta) were
immunized with two topical administrations (weeks 0, 6) of
DermaVirSHIV. Three of these animals (M33, M34, M38)
were given one additional administration of DermaVirSHIV
(week 12). All five macaques were subsequently boosted (at
week 18 for M33, M34, M38; at week 12 for M35, M37) by
IM route, with SHIV89.6P gp140 and p27 Gag proteins
formulated in QS-21 (Antigenics, Woburn, MA). Macaques
M33, M34 and M38 were also given one additional protein
administration at week 37. The DermaVir prime dose was
100 μg of DNA and the protein boost dose was 300 μg (150 μg
each) protein with 100 μg QS-21. Following immunization,
macaques were challenged rectally with SHIV162P3 at week 48.
Naive animals were not challenged at the same time as the
immunized macaques but were exposed to the same challenge
dose as the immunized animals. PBMC were isolated 2 weeks
following immunizations and following viral challenge, as
specified in figure legends, and immunological assays were
performed.
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CTL activity was assessed using a single cell-based two-
color flow cytometric cytotoxicity assay, CytoToxiluxR (Onco-
Immunin, Inc., Gaithersburg, MD) as previously described (Liu
et al., 2002, 2004).
IFNγ ELISPOT
The IFNγ ELISPOT assay was performed with murine
splenocytes using a mouse-specific kit from Ucytech (Nether-
lands) according to the manufacturer's protocol whereas
ELISPOT assays with rhesus PBMC were performed as
previously described (Cristillo et al., 2006).
Intracellular cytokine staining
Splenocytes were stimulated for 5 h with either Gag or
Env peptide pools (1 μg/ml) or with PMA (2.5 ng/ml) plus
Ionomycin (1.5 μM). Following stimulation, cell surface
staining was carried out using rat anti-mouse FITC-conjugated
anti-CD3, PerCP-conjugated anti-CD4 and APC-conjugated
anti-CD8 monoclonal antibodies (BD Biosciences, San Jose,
CA). Intracellular cytokine staining was carried out using rat
anti-mouse PE-conjugated TNFα (Th1) or IL-4 (Th2) mono-
clonal antibodies followed by cytometry analysis. The %
peptide-specific Th1- or Th2-positive cells were calculated
using the following subtraction: %Th1=%Th1 (peptide-
stimulated splenocytes from immunized mice)−%Th1 (unsti-
mulated splenocytes from immunized mice). To ensure that the
TNFα and IL-4 intracellular cytokine levels reported reflect
immunization-specific cellular immune responses, values
obtained from unvaccinated, naive control animals were also
subtracted from those of vaccinated animals. In general, the
background levels found in naive animals were less than 0.5%
(data not shown). Where indicated, intracellular cytokine
staining in mice was performed using anti-mouse FITC-
conjugated CD44 antibody, APC-conjugated CD62L, PerCP-
conjugated CD4 antibody and PE-conjugated TNFα antibody
(BD Biosciences).
Cytometric bead array
Cytometric bead array (BD Biosciences, San Diego, CA)
was performed to quantitate secreted Th1 (IFNγ, IL-2, TNFα)
and Th2 (IL-4, IL-5, IL-6) cytokines from rhesus PBMC.
Briefly, PBMC (2×106 cells/ml) from vaccinated macaques
were stimulated for 24 h with either Env (1 μg/ml) or Gag (1 μg/
ml) peptide pools or were left unstimulated in 96-well plates at
37 °C, 5% CO2. Following stimulation, cells were transferred to
Eppendorf microcentrifuge tubes and were centrifuged at 300×g
for 5 min. Cell supernatants (50 μl) were mixed with capture
beads and PE detection reagent. Dilutions of Th1/Th2 cytokine
standards were also mixed with capture beads and PE detection
reagents. All samples were incubated in the dark at room
temperature for 3 h and were subsequently washed with 1 ml of
wash buffer (BD Biosciences, San Diego, CA) followed bycentrifugation for 5 min at 200×g. Samples were resuspended in
300 μl of wash buffer, and beads were acquired using a
FACScalibur cytometer (BD Biosciences, San Diego, CA).
Levels of cytokines were quantitated using the BD CBA 6-Bead
Analysis Software.
Binding antibody assay
Serum samples were tested for Env gp140- and Gag p27-
specific antibodies using an enzyme-linked immunosorbent
assay (ELISA) as previously described (Pal et al., 2002). Serum
titers were determined as the highest dilution of immune serum-
producing ELISA values (A450 nm) greater than or equal to two
times the binding detected with a corresponding dilution of pre-
immune serum. As expected, serum from naive animals had no
reactivity with Env gp140 and Gag p27 antigens in the ELISA
(data not shown).
Central memory ICS
Vaccine-specific CD8 and CD4 central memory (CD45RA−/
CCR7+) T cells were quantified by flow cytometry as described
(Peng et al., 2006). Rhesus PBMC were suspended in complete
RPMI (3×106 cells/ml) and were either left untreated or
stimulated for 6 h with Env, Gag or irrelevant (LCMV) peptide
pool (1 μg/ml) at 37 °C, 5% CO2. All cells were co-stimulated
with CD28 (1 μg/ml) and CD49d (1 μg/ml) in the presence of
Golgi Plug (1 μg/ml). Following stimulation, cells were
collected and washed with FACS wash buffer (0.05% sodium
azide, 0.1% FBS, 1× PBS). Cells were surface stained using
mouse anti-human FITC-conjugated anti-CD45RA and PE-
Cy7-conjugated anti-CD8 (BD BioSciences), and also stained
for CCR7 using purified anti-CCR7 (IgM isotype) and anti-IgM-
PE antibodies (BD BioSciences). Intracellular cytokine staining
was then carried out per the manufacturer's protocol using
mouse anti-human APC-conjugated TNFα monoclonal anti-
body. Cells were acquired (minimum of 10,000 CD8 memory
and 20,000 CD4 memory cells) using a FACScalibur cytometer
and analysis was performed using Cell Quest software (BD
BioSciences). Positive responses were defined as responses
obtained in peptide-stimulated samples that were at least twofold
greater than unstimulated controls and greater than the irrelevant
peptide-stimulated control. Values reported represent vaccine
(peptide)-specific responses as determined by the following
sample calculation: %CD8+CD45RA−CCR7+TNFα+ (stim)−
%CD8+CD45RA−CCR7+TNFα+ (unstim).
Virological assays to monitor challenge outcome
Animals were bled periodically following challenge and
viral load in plasma was assessed using a more sensitive
nucleic acid sequence-based amplification assay (NASBA) to
quantitate SIV RNA (Romano et al., 2000). Viral RNA load
in necropsied tissues was quantitated as described elsewhere
(Pal et al., 2006b). The NASBA assay, performed on plasma
samples, has a lower limit of sensitivity of 50 copies of SIV
RNA per milliliter of plasma whereas the assay performed on
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confirm virus transmission, PBMC and tissues collected from
animals following virus challenge were subjected to qualita-
tive virus isolation by co-culturing with PHA-activated
human PBMC (Pal et al., 2002). In addition, a quantitative
real-time PCR assay was conducted for the detection and
quantitation of proviral DNA in the PBMC and tissues of
animals.
Spearman rank correlation analysis
A Spearman rank correlation analysis was performed using
GraphPad Prism software (version 3.03). The analysis
included the %CD8+CD45RA−CCR7+Th1+ or %CD8−CD45-
RA−CCR7+Th1+ cells on the day of SHIV162P3 challenge
and plasma viral RNA load (Area Under the curve) for days
21–84.
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